Glutamate pyruvate transaminase 2 mRNA (GPT2 mRNA)

Glutamate pyruvate transaminase 2 (GPT2) mRNA encodes a mitochondrial enzyme that catalyzes the reversible transamination between alanine and 2-oxoglutarate to form pyruvate and glutamate (1.3.1, 1.3.4). This reaction serves as a critical metabolic junction, linking amino acid metabolism to the tricarboxylic acid (TCA) cycle through anaplerosis, which is essential for maintaining cellular energy and providing biosynthetic precursors (1.3.1, 1.3.3). In oncology, GPT2 is frequently upregulated to support the high metabolic demands of rapidly proliferating cells, particularly in aggressive subtypes like triple-negative breast cancer and colorectal cancer, where it facilitates metabolic reprogramming and metastasis (1.3.4). Conversely, biallelic loss-of-function mutations in the GPT2 gene are associated with severe neurodevelopmental disorders, including intellectual disability, microcephaly, and progressive motor symptoms, highlighting its vital role in brain development (1.3.1, 1.3.5). Therapeutic strategies targeting GPT2 mRNA, such as siRNA or antisense oligonucleotides, are being explored to inhibit tumor growth by disrupting these metabolic adaptations (1.4.1, 1.4.3). However, the development of such therapies must account for the enzyme's essential functions in normal neurological and systemic metabolism to minimize potential adverse effects (1.3.5, 1.4.5).

Other names

Alanine aminotransferase 2 mRNAALT2 mRNAGlutamic-pyruvic transaminase 2 mRNAMRT49 mRNANEDSPM mRNA

RNA interference (RNAi) or antisense inhibition leading to the degradation of the target mRNA and subsequent reduction in protein translation.